Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration

Supportive Care in Cancer

Volumn 6, Issue 3, 1998, Pages 237-243

  Gandara, David R ^a,g   Roila, Fausto ^b   Warr, David ^c   Edelman, Martin J ^a,d   Perez, Edith A ^e   Gralla, Richard J ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b POLICLINICO MONTELUCE   (Italy)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^e MAYO CLINIC   (United States)

^f OCHSNER CLINIC FOUNDATION   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy induced emesis; Dolesetron; Granisetron; Ondansetron; Serotonin receptors; Tropisetron

Indexed keywords

DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG USE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VOMITING; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; EVIDENCE BASED MEDICINE; NEOPLASM; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 0031596456     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050160     Document Type: Review

References (65)

1. Anderson H, Thatcher N, Howell A, et al (1994) Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. Eur J Cancer 30:610-615
2. Andrews PLR, Davis CJ (1993) The mechanism of emesis induced by anti-cancer therapies. In: Andrews PLR, Sanger GJ (eds) Emesis in anticancer therapy, mechanisms and treatment. Chapman & Hall, London, pp 14-17
3. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester KP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:(12):1969-1975
4. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chiang A, Galvin D, Hart NE (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413
5. Bleiberg HH, Spielmann M, Falkson C et al (1995) Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: dose ranging study. Clin Therapeutics 17:38-51
6. Bonneterre J, Chevalier B, Metz R, et al (1990) A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8:1063-1069
7. Bremer K. on behalf of the Granisetron Study Group (1992) A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer [A] 28:1018-1022
8. Buser KS, Joss RA, Piquet D, et al. (1993) Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo controlled study. Ann Oncol 4:475-479
9. Campora E, Giudici S, Merlini L, et al (1994) Ondansetron and dexamethasone versus standard combination antiemetic therapy. Am J Clin Oncol (CCT) 17:522-526
10. Chevalier B (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 [Suppl 1]:S33-S36
11. Clavel M, Bonneterre J, d'Allens H, French Ondansetron Study Group (1995) Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. Eur J Cancer [A] 31:15-19
12. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. Am J Clin Oncol 17:137-146
13. De Mulder PHM, Seynaeve C, Vermerken JB, et al (1990) Ondansetron (GR38032F) versus high dose metoclopramide in the prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840
14. De Nigris A, Paladini G, Giosa F, et al (1994) Tropisetron (Navoban) compared with alizapride in the control of emesis induced by cyclophosphamide-containing resimens. Eur J Cancer [A] 30:1902-1903
15. Dicato MA (1991) Oral treatment with ondansetron in the outpatient setting. Eur J Cancer 27 [Suppl 1]:518-519
16. Ettinger DS, Eisenbers PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K (1996) A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patient receiving moderately emetogenic chemotherapy. Cancer 78:144-151
17. Evidence-Based Medicine Working Group (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 268:420-425
18. Reference deleted
19. Fox SM, Einhorn LH, Cox E, et al (1993) Ondansetron vs ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
20. Gralla RJ, Popovic W, Strupp J, Culleton V, Preston A, Friedman C (1997) Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron versus IV ondansetron. Proc Am Soc Clin Oncol 16:52a (#178)
21. Granisetron Study Group (1993) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 199:555-559
22. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
23. Grunberg SM, Stevenson LL, Russell CA, et al (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137-1141
24. Grunberg SM, Lane M, Lester EP, Sridhar KS, Monimer J, Murphy W, Sanderson PE (1993) Randomized double blind comparison of three dose levels of intravenous ondansetron in the prevention of cispiatin-induced emesis. Cancer Chemother Pharmacol 32:268-272
25. Hacking A (1992) Oral granisetron - simple and effective. A preliminary report. Granisetron Study Group. Eur J Cancer [Suppl 1]:S28-S32
26. Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with hish-dose cisplatin chemotherapy. J Clin Oncol 9:721-728
27. Heron JF (1995) Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethason and high-dose metoclopramide plus dexamethasone. Semin Oncol 22 [Suppl 10]:24-30
28. Herrstedt J (1996) New perspectives in antiemetic treatment. Support Care Cancer 4:416-119
29. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
30. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705
31. Hesketh PJ, Harvey WH, Harker WG, et al (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600
32. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W, for the Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249
33. Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810
34. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
35. Jones AL, Hill AS, Soukop M, et al (1991) Comparison of ondansetron and dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483-487
36. Kaasa S, Kvaloy S, Dicato MA, et al (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 26:311-314
37. Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057
38. Kris MG, Gralla RJ, Clark RA, et al (1988) Dose-ranging evaluation of the serotonin antagonist GRC507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy J Clin Oncol 6:659-662
39. Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II triais of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Institute 81:42-16
40. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zarentsky SA, Litsey D, Tyson LB, Schmidt L, Hahne WF (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
41. Levin M, Warr D, Yell L, et al 1993) Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with eyclophosphamide, methotrexate and fluorouracil. N Engl J Med 328:1081-1084
42. Marschner NW, Adler M, Nagel GA, et al (1991) Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27:1137-1140
43. 3 antagonist, versus a standard antiemetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26 [Suppl 1]:S28-S32
44. Many M, Pouillart P, Scholl S (1990) Comparison of the 5-nydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metaclopromide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
45. Marty M, Kleisbauer J-P, Fournet P, Vergnenegro A, Caries P, Loria-Kanza Y, Simonetta C, Bruijn KM de, the French Navoban Study Group (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anticancer Drugs 6:15-21
46. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of Granisetron, a selective 5-hydroxy-tryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204-2210
47. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D on behalf of the Granisetron Study Group (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-mduced emesis. J Clin Oncol 12:1242-1245
48. Nicolai N, Mangiarotti B, Salvioni R, et al (1993) Dexamethasone plus ondansetron versus dexamethasone plus alizapride in the prevention of emesis induced by cisplatin-containing chemotherapies for urological cancers. Eur Urol 23:450-456
49. Palmer R, Moriconi W, Cohn J, et al (1995) A double-blind comparison of the efficacy and safety of oral granisetron with oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapv. Proc Am Soc Clin Oncol 14:528 (# 1740)
50. Perez EA, Hesketh PJ, Gandara DR (1991) Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol 18 [Suppl 3]:73-80
51. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043
52. Perez EA, Chawla SP, Kaywin PK, Sandbach K, Yocom K, Preston A, Friedman C (1997) Efficacy and safety of oral granisetron versus IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 16:43a (#149)
53. Rath U, Upadhyaya BK, Arechavala E, et al (1993) Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 50:168-172
54. Riviere A. on behalf of the Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971
55. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678
56. Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF (1997) Randomized, double-blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer 79:1216-24
57. Ruff P, Paska W, Goedhals L, Pouiliart P, Riviere A, Vorolieof D, Bloch, Jones A, Martin, Brunet R, Butcher, Forster J, McQuade B, on behalf of the Ondansetron and Granisetron Emesis Study Group (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 51:113-118
58. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, de Mulder PHM, on behalf of the Ondansetron Study Group (1992) Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 66:192-197
59. Sledge GW, Einhorn L, Nagy C, et al (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528
60. Soukop M, McQuade B, Hunter E, et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304
61. Soukop M, on behalf of the Granisetron Study Group (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177-183
62. 1 receptor antagonist CP-99,994. Neuropharmacocology 33:259-260
63. Thant M, Pendergras K, Harman G, Modiano M, Martin L, DuBois D, Cramer M, Hahne W (1996) Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin chemotherapy (CCT). Proc Am Soc Clin Oncol 15:533 (#1727)
64. Van Belle SJ-P, Stamatakis L, Bleiberg H, Cocquyt FJ, Michel J, de Bruijn KM (1994) Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 5:821-825
65. Warr D, Willan A, Fine S, et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83:1169-1173